| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5833789 | International Immunopharmacology | 2011 | 25 Pages |
Leishmaniasis is a diverse group of clinical syndromes caused by protozoan parasites of the genus Leishmania. The clinical manifestation of the disease varies from self-limiting cutaneous lesions to progressive visceral disease. It is estimated that 350Â million people are at risk in 88 countries, with a global incidence of 1-1.5Â million cases of cutaneous and 500,000 cases of visceral leishmaniasis. The key control measures mainly rely on early case detection and chemotherapy which has been hampered by the toxicity of drugs, side-effects and by the emergence of drug resistance in parasites. Control of reservoir host and vector is difficult due to operational difficulties and frequent relapses in the host. Therefore, the development of effective and affordable vaccine against leishmaniasis is highly desirable. Although considerable progress has been made over the last decade in understanding immune mechanisms underlying potential candidate antigens, including killed, live attenuated parasites, crude parasites, pure or recombinant Leishmania proteins or DNA encoding leishmanial proteins, as well as immunomodulators from sand fly saliva, very few candidate vaccines have progressed beyond the experimental stage. As such there is no vaccine against any form of human leishmaniasis. In recent years, however, much interest has been stimulated towards vaccination against leishmaniasis focused mainly on cutaneous leishmaniasis with fewer attempts against visceral leishmaniasis.
Research Highlights⺠Vaccine candidates, based on recombinant protein and DNA, against leishmaniasis is described. ⺠Includes live attenuated and killed Leishmania vaccines. ⺠Self-explanatory description in tables with reference to the immune response and other outcomes of study.
